RDHL Stock - RedHill Biopharma Ltd.
Unlock GoAI Insights for RDHL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $8.04M | $6.53M | $61.80M | $85.76M | $64.36M |
| Gross Profit | $4.85M | $3.07M | $28.46M | $36.35M | $27.47M |
| Gross Margin | 60.3% | 47.0% | 46.1% | 42.4% | 42.7% |
| Operating Income | $-14,613,000 | $12.63M | $-42,844,000 | $-81,135,000 | $-63,684,000 |
| Net Income | $-8,268,000 | $23.92M | $-71,669,000 | $-97,744,000 | $-76,173,000 |
| Net Margin | -102.8% | 366.2% | -116.0% | -114.0% | -118.4% |
| EPS | $-7.00 | $46.00 | $-600.00 | $-1000.00 | $-1000.00 |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Visit WebsiteEarnings History & Surprises
RDHLEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 5, 2025 | — | $-1.15 | — | — |
Q2 2025 | Jun 14, 2025 | — | — | — | — |
Q2 2025 | Apr 10, 2025 | — | — | — | — |
Q4 2024 | Oct 3, 2024 | — | $900.00 | — | — |
Q3 2024 | Aug 29, 2024 | $-30.00 | $-200.00 | -566.7% | ✗ MISS |
Q2 2024 | Apr 8, 2024 | — | — | — | — |
Q1 2024 | Feb 12, 2024 | $-0.03 | $-0.20 | -566.7% | ✗ MISS |
Q4 2023 | Dec 29, 2023 | — | — | — | — |
Q2 2023 | Jun 30, 2023 | — | $4.83 | — | — |
Q2 2023 | Jun 12, 2023 | — | $146.75 | — | — |
Q1 2023 | Mar 27, 2023 | — | $1.07 | — | — |
Q4 2022 | Nov 7, 2022 | $-0.30 | $-2.00 | -566.7% | ✗ MISS |
Q3 2022 | Sep 23, 2022 | — | $-10.04 | — | — |
Q2 2022 | Jun 23, 2022 | $-4.00 | $-3.00 | +25.0% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-4.00 | $-5.00 | -25.0% | ✗ MISS |
Q4 2021 | Nov 30, 2021 | $-4.80 | $-4.60 | +4.2% | ✓ BEAT |
Q3 2021 | Aug 26, 2021 | $-4.00 | $-6.20 | -55.0% | ✗ MISS |
Q2 2021 | May 27, 2021 | $-4.60 | $-5.30 | -15.2% | ✗ MISS |
Q1 2021 | Mar 18, 2021 | $-4.50 | $-7.00 | -55.6% | ✗ MISS |
Q4 2020 | Nov 12, 2020 | $-2.20 | $-5.00 | -127.3% | ✗ MISS |
Latest News
RedHill Biopharma Shared In Vivo Results, Indicating That Opaganib Combined With Venetoclax Reduces Chronic Lymphocytic Leukemia Cells By Half Compared To Controls
📈 PositiveRedHill Biopharma Regains Nasdaq Compliance
📈 PositiveRedHill Biopharma Wins ~$10.5M Judgment Against Kukbo; RedHill Has Secured A Korean Court Attachment Grant Against Kukbo Aimed At Preventing Kukbo From Disposing Of Assets Prior To Judgment Enforcement
📈 PositiveCPIX stock has given up its prior gain. Cumberland Pharmaceuticals shares were trading higher after the company invested $4M for a 30% ownership stake in RedHill's global Talicia business.
➖ NeutralCumberland To Co-Commercialize Talicia With RedHill, For The Treatment Of Helicobacter Pylori Infection In Adults, A Bacterial Infection And Leading Risk Factor For Gastric Cancer
📈 PositiveRedHill shares are trading higher after Cumberland Pharmaceuticals invested $4M for a 30% ownership stake in its global Talicia business.
📈 PositiveCumberland Pharmaceuticals shares are trading higher after the company invested $4M for a 30% ownership stake in RedHill's global Talicia business.
📈 PositiveCumberland Pharmaceuticals Invests $4M For A 30% Ownership Stake In RedHill's Global Talicia Business
📈 PositiveRedHill Biopharma Licenses FDA-Approved H. pylori Therapy Talicia For Middle East Expansion In Deal Valued At Up To $1.8M, Plus Tiered Sales Royalties
📈 PositiveRedHill Granted $8.25M Original Award Plus $1.82M Legal Costs As New York Court Rules Against Kukbo Again
📈 PositiveRedhill Biopharma H1 Sales $4.079M Up From $2.572M YoY
📈 PositiveRedHill Received Announces Receipt Of $1.1M In Talicia Licensing Payments
📈 PositiveFrequently Asked Questions about RDHL
What is RDHL's current stock price?
What is the analyst price target for RDHL?
What sector is RedHill Biopharma Ltd. in?
What is RDHL's market cap?
Does RDHL pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RDHL for comparison